International Medical Science Research Journal, Volume 4, Issue 3, March 2024

OPEN ACCESS
International Medical Science Research Journal
P-ISSN: 2707-3394, E-ISSN: 2707-3408
Volume 4, Issue 3, No.284-294, March 2024
DOI: 10.51594/imsrj.v4i3.920
Fair East Publishers
Journal Homepage: www.fepbl.com/index.php/imsrj

ENHANCING MEDICATION QUALITY CONTROL IN

NIGERIA: A COMPREHENSIVE ANALYSIS OF
REGULATORY CHALLENGES AND SOLUTIONS

Michael Alurame Eruaga¹, Esther Oleiye Itua², & James Tabat Bature³

¹National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria
²National Agency for Food and Drug Administration and Control (NAFDAC),
Edo State, Nigeria
³National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria
___________________________________________________________________________
Corresponding Author: Michael Alurame Eruaga
Corresponding Author Email: eruagus2@gmail.com

Article Received: 01-01-24 Accepted:10-03-24 Published: 18-03-24

Licensing Details: Author retains the right of this article. The article is distributed under the terms of
the Creative Commons Attribution-Non Commercial 4.0 License
(http://www.creativecommons.org/licences/by-nc/4.0/), which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is
attributed as specified on the Journal open access page.
___________________________________________________________________________
ABSTRACT
Medication quality control in Nigeria faces multifaceted challenges rooted in regulatory
inefficiencies, infrastructural limitations, and systemic inadequacies. This study undertakes a
comprehensive analysis of these challenges while proposing pragmatic solutions to bolster the
quality control framework in the Nigerian pharmaceutical sector. Drawing upon extensive
literature review and expert insights, the research identifies key regulatory challenges impeding
effective medication quality control in Nigeria. These challenges encompass inadequate
regulatory capacity, inconsistent enforcement mechanisms, rampant substandard and
counterfeit medications, and limited access to essential medicines. Additionally, infrastructural
deficiencies such as inadequate laboratory facilities and insufficient human resources further
exacerbate the problem, leading to compromised patient safety and public health risks. In
response to these challenges, the study proposes a multifaceted approach to enhance medication
quality control in Nigeria. This includes strengthening regulatory frameworks through

Eruaga, Itua, & Bature, P.No. 284-294 Page 284

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

legislative reforms aimed at bolstering enforcement capabilities and harmonizing standards

with international best practices. Moreover, improving regulatory capacity through training
programs and investment in state-of-the-art laboratory infrastructure is essential to enhance
surveillance and detection of substandard medications. Furthermore, fostering collaboration
between regulatory agencies, healthcare providers, and pharmaceutical manufacturers is
imperative to streamline supply chains and ensure the integrity of medications from production
to distribution. Additionally, public awareness campaigns and community engagement
initiatives play a pivotal role in empowering consumers to make informed decisions and report
instances of substandard medications. By addressing these regulatory challenges and
implementing comprehensive solutions, Nigeria can significantly enhance medication quality
control, safeguard patient health, and foster a conducive environment for pharmaceutical
innovation and growth.
Keywords: Medical, Medication, Drugs, Quality Control, Nigeria, Regulations, Review.
___________________________________________________________________________
INTRODUCTION
The pharmaceutical sector in Nigeria plays a vital role in providing essential healthcare services
to its population of over 200 million people (Oseni, and Oseni, 2017; Obuaku, 2014). With a
diverse range of diseases and health challenges, access to quality medications is crucial for
ensuring effective treatment and improving public health outcomes. However, the sector
grapples with numerous regulatory challenges that impede the assurance of medication quality
and safety.
Nigeria's pharmaceutical sector is characterized by a mix of multinational corporations, local
manufacturers, and importers catering to the diverse healthcare needs of its populace
(NIGERIA’S, 2023). Despite the sector's potential for growth and innovation, it faces
significant hurdles such as infrastructural deficiencies, supply chain inefficiencies, and
regulatory bottlenecks. These challenges not only hinder the sector's development but also pose
risks to public health by compromising the quality and efficacy of medications available to
patients.
Medication quality control is paramount for safeguarding public health and ensuring the
efficacy and safety of pharmaceutical products (World Health Organization, 2 000; Dixon,
1999.). Poor-quality medications, including substandard and counterfeit drugs, pose grave risks
to patients, ranging from treatment failure to adverse reactions and even mortality. Moreover,
the proliferation of such medications undermines trust in the healthcare system and hampers
efforts to combat diseases effectively. Therefore, robust medication quality control mechanisms
are indispensable for maintaining the integrity of the pharmaceutical supply chain and
protecting patient well-being (Galletly, and Pinkerton, 2006; World Health Organization,
2017).
Nigeria's medication quality control efforts are hampered by a myriad of regulatory challenges.
These include inadequate regulatory capacity, inconsistent enforcement mechanisms, rampant
circulation of substandard and counterfeit medications, and limited access to essential
medicines. Additionally, infrastructural deficiencies, such as inadequate laboratory facilities
and insufficient human resources, further exacerbate the problem. Addressing these challenges
requires a comprehensive understanding of their root causes and the development of targeted

Eruaga, Itua, & Bature, P.No. 284-294 Page 285

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

solutions to strengthen the regulatory framework and enhance medication quality control
processes (Olowofela, et al., 2017; Afolabi, 2013).
In light of these challenges, this study undertakes a comprehensive analysis to identify
regulatory bottlenecks hindering medication quality control in Nigeria and proposes pragmatic
solutions to address them effectively. By shedding light on these issues and advocating for
regulatory reforms, this research aims to contribute to the enhancement of medication quality
control practices, thereby advancing public health and fostering sustainable development in
Nigeria's pharmaceutical sector.
Regulatory Challenges in Medication Quality Control
Inadequate regulatory capacity poses a significant challenge to medication quality control in
Nigeria (Garuba, et al., 2009; Ogbonna, et al., 2015). Regulatory agencies responsible for
overseeing the pharmaceutical sector often lack the necessary resources, expertise, and
infrastructure to effectively monitor and enforce quality standards (Lawrence, and Woodcock,
2015; Pezzola, and Sweet, 2016; Kohler, et al., 2016). Limited funding and staffing shortages
further exacerbate these challenges, leading to gaps in regulatory oversight and enforcement.
As a result, many pharmaceutical products may enter the market without undergoing rigorous
quality assessments, increasing the risk of substandard or counterfeit medications reaching
consumers (Nsimba, 2009; György, 2018).
Inconsistent enforcement mechanisms contribute to the proliferation of substandard and
counterfeit medications in Nigeria. Regulatory agencies may face challenges in coordinating
efforts across different regions, leading to disparities in enforcement actions and regulatory
oversight. Additionally, corruption and lack of accountability within regulatory bodies can
undermine enforcement efforts, allowing unscrupulous actors to circumvent regulations and
distribute low-quality or counterfeit drugs with impunity. Without consistent and transparent
enforcement mechanisms, it becomes difficult to deter illegal practices and ensure compliance
with quality standards throughout the pharmaceutical supply chain (Haji, 2023; Liang, and
Mackey, 2009).
The widespread circulation of substandard and counterfeit medications poses a grave threat to
public health in Nigeria (Akinyandenu, 2013). These products may contain insufficient active
ingredients, incorrect dosages, or harmful contaminants, putting patients at risk of treatment
failure, adverse reactions, or even death. The prevalence of counterfeit medications is fueled by
factors such as weak regulatory oversight, porous borders, and the profitability of illicit drug
trade. Despite efforts to combat this issue, including the introduction of regulatory measures
and public awareness campaigns, counterfeiters continue to exploit vulnerabilities in the supply
chain, making it challenging to eradicate the problem entirely (Buckley, and Gostin, 2013;
Mackey, 2013).
Limited access to essential medicines remains a significant barrier to healthcare delivery in
Nigeria (Obuaku, 2014; Amadi, and Tsui, 2019.). While medication quality control efforts aim
to ensure the availability of safe and effective pharmaceutical products, disparities in access
persist due to factors such as geographical remoteness, affordability constraints, and supply
chain disruptions. Vulnerable populations, including those in rural areas and underserved
communities, are particularly affected by these access barriers, leading to disparities in health
outcomes and exacerbating existing inequalities in healthcare access (Douthit, et al., 2015; Cyr,
et al., 2019; Diaz, et al., 2021).

Eruaga, Itua, & Bature, P.No. 284-294 Page 286

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

Infrastructural deficiencies, including inadequate laboratory facilities and human resources,

hinder medication quality control efforts in Nigeria (Wilson, et al., 2018; Efe, 2013). Many
regulatory agencies lack the necessary laboratory equipment and trained personnel to conduct
comprehensive quality assessments of pharmaceutical products. Furthermore, insufficient
investment in infrastructure development and capacity-building initiatives limits the ability of
regulatory agencies to effectively monitor and respond to emerging challenges in medication
quality control. Without adequate infrastructure and human resources, regulatory agencies
struggle to fulfill their mandate of safeguarding public health and ensuring the quality and safety
of medications available in the Nigerian market (Ndomondo-Sigonda, et al., 2017; Ncube, et
al., 2021; Ekeigwe, 2019).
In conclusion, addressing regulatory challenges in medication quality control requires a
multifaceted approach that addresses systemic issues such as inadequate regulatory capacity,
inconsistent enforcement mechanisms, the proliferation of substandard and counterfeit
medications, limited access to essential medicines, and infrastructural deficiencies. By
strengthening regulatory frameworks, enhancing enforcement mechanisms, improving access
to quality medicines, and investing in infrastructure development, Nigeria can mitigate the risks
associated with poor-quality medications and safeguard the health and well-being of its
population.
Analysis of Regulatory Challenges
Each regulatory challenge in medication quality control in Nigeria requires a detailed
examination to understand its complexity and implications fully. This involves assessing the
extent of inadequate regulatory capacity, inconsistent enforcement mechanisms, the
proliferation of substandard and counterfeit medications, limited access to essential medicines,
and infrastructural deficiencies. By delving into the specific nuances of each challenge,
stakeholders can develop targeted strategies to address underlying issues and improve
medication quality control processes (Awele, 2021; Höllein, et al., 2016).
The regulatory challenges in medication quality control have a profound impact on patient
safety and public health in Nigeria. Substandard and counterfeit medications jeopardize patient
well-being by exposing them to ineffective treatments, adverse reactions, and health
complications. Inadequate access to essential medicines further exacerbates health disparities
and undermines efforts to combat diseases effectively. Moreover, weak regulatory oversight
and enforcement mechanisms erode public trust in the healthcare system, leading to diminished
confidence in pharmaceutical products and healthcare services overall (Taylor, et al., 2001;
Yakubu, et al., 2020).
Various contributing factors and root causes underlie the regulatory challenges in medication
quality control in Nigeria. These may include institutional weaknesses, corruption, insufficient
funding, lack of political will, and gaps in regulatory frameworks. Additionally, socioeconomic
factors such as poverty, illiteracy, and limited healthcare infrastructure exacerbate the problem
by creating opportunities for the proliferation of substandard and counterfeit medications
(Yakubu, 2020; Ndichu, et al., 2019). Understanding these underlying factors is essential for
devising effective solutions that address systemic issues and promote sustainable improvements
in medication quality control.

Eruaga, Itua, & Bature, P.No. 284-294 Page 287

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

Solutions to Enhance Medication Quality Control

Implementing comprehensive legislative reforms to strengthen regulatory frameworks and
enhance the authority and capacity of regulatory agencies to enforce quality standards
effectively (Rodrigo, et al., 2009). Aligning regulatory standards and practices with
international best practices to ensure consistency and compatibility with global quality
standards, thereby facilitating trade and enhancing consumer protection. Providing specialized
training programs and capacity-building initiatives for regulatory personnel to enhance their
skills and expertise in medication quality control, regulatory compliance, and enforcement
(Glover, et al., 2018). Allocating resources for the establishment and enhancement of laboratory
infrastructure, including equipment, facilities, and quality assurance systems, to enable robust
quality testing and analysis of pharmaceutical products (Mukherjee, 2019; ).
Fostering collaboration and coordination among regulatory agencies at the national, regional,
and local levels to enhance information sharing, joint inspections, and enforcement actions
against violators of quality standards. Implementing measures to strengthen supply chain
management, including traceability systems, inventory control mechanisms, and stringent
import and export controls, to prevent the entry and distribution of substandard and counterfeit
medications.
Launching public awareness campaigns and educational programs to empower consumers with
knowledge about medication quality, safety, and regulatory rights, enabling them to make
informed decisions and demand quality-assured products. Establishing channels for reporting
suspected cases of substandard and counterfeit medications to regulatory authorities, healthcare
providers, and consumer protection agencies, facilitating prompt investigation and enforcement
actions against violators.
By implementing these comprehensive solutions, Nigeria can enhance medication quality
control, mitigate regulatory challenges, and safeguard patient safety and public health
effectively.
Implementation Strategies
The prioritization of solutions for enhancing medication quality control in Nigeria should be
guided by the urgency of addressing specific regulatory challenges and the feasibility of
implementing proposed interventions. Solutions addressing critical issues with immediate and
severe impacts on patient safety and public health should be prioritized. For example, initiatives
targeting the proliferation of substandard and counterfeit medications may take precedence due
to their significant negative consequences. Feasibility considerations encompass factors such
as available resources, regulatory capacity, political will, and stakeholder support. Solutions
that can be implemented with existing resources and infrastructure should be prioritized, while
more ambitious reforms may require phased implementation and additional support (Awele,
2021).
Developing a clear and realistic timeline for the implementation of solutions is essential for
ensuring accountability and measuring progress. The timeline should outline specific
milestones, deadlines, and benchmarks for each proposed intervention. Short-term, medium-
term, and long-term goals should be established to facilitate gradual progress towards enhancing
medication quality control. Prioritized solutions with immediate impact and feasibility should
be implemented first, followed by initiatives requiring longer-term planning and investment.

Eruaga, Itua, & Bature, P.No. 284-294 Page 288

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

Regular reviews and updates to the implementation timeline may be necessary to accommodate
unforeseen challenges and adjust strategies as needed (Queen, et al., 2023).
Effective implementation of solutions requires the allocation of adequate resources and
delineation of responsibilities among relevant stakeholders. Financial resources should be
allocated to fund priority initiatives, including regulatory capacity-building, infrastructure
development, training programs, and public awareness campaigns. Human resources, including
regulatory personnel, technical experts, and healthcare professionals, should be mobilized to
support implementation efforts. Clear roles and responsibilities should be assigned to regulatory
agencies, government agencies, industry stakeholders, healthcare providers, and civil society
organizations to ensure coordinated action and accountability. Collaboration and partnerships
between public and private sectors, as well as international cooperation, can leverage resources
and expertise to enhance medication quality control effectively (Opeyemi, et al., 2024).
Evaluation and Monitoring
Establishing metrics and indicators for assessing the effectiveness of implemented solutions is
essential for evaluating progress and identifying areas for improvement. Key performance
indicators (KPIs) may include measures of medication quality, such as the prevalence of
substandard and counterfeit medications, adherence to regulatory standards, and consumer
confidence in pharmaceutical products. Other metrics may focus on regulatory capacity,
enforcement outcomes, access to essential medicines, and public awareness levels. Baseline
data should be collected prior to implementation to establish benchmarks, and regular
monitoring and evaluation should track changes over time. Qualitative feedback from
stakeholders and beneficiaries can complement quantitative data to provide a comprehensive
understanding of the impact of implemented solutions (Zeitz, et al., 1993; Berendes, et al.,
2013).
Continuous monitoring and evaluation are critical for identifying emerging challenges,
evaluating the effectiveness of implemented strategies, and making informed adjustments as
needed. Regular reviews of progress against established KPIs can inform decision-making and
identify areas requiring corrective action. Stakeholder consultations, feedback mechanisms, and
periodic assessments can provide valuable insights into the effectiveness of interventions and
areas for improvement. Flexibility and adaptability are essential, as regulatory challenges and
external factors may evolve over time. Strategies should be responsive to changing
circumstances and updated accordingly to ensure ongoing effectiveness in enhancing
medication quality control and safeguarding public health. By prioritizing implementation
strategies, establishing clear timelines and responsibilities, and implementing robust monitoring
and evaluation mechanisms, Nigeria can make significant strides in enhancing medication
quality control and improving public health outcomes (NNEOMA, and OBINNA, 2021;
Conway, et al., 2013).
Future Outlook
As Nigeria strives to enhance medication quality control, several key trends and developments
will shape the future landscape of pharmaceutical regulation and public health. One significant
trend is the increasing globalization of the pharmaceutical supply chain. With the expansion of
international trade and the growing interconnectedness of markets, regulatory agencies must
adapt to oversee the quality and safety of pharmaceutical products imported into Nigeria.
Strengthening collaboration with international partners and adopting harmonized regulatory

Eruaga, Itua, & Bature, P.No. 284-294 Page 289

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

standards will be crucial in addressing the challenges posed by cross-border trade in

medications. Advancements in technology offer opportunities to improve medication quality
control processes (Raphael, 2011; Agwu, 2014). The use of blockchain technology, for
instance, can enhance transparency and traceability throughout the pharmaceutical supply
chain, helping to prevent the entry of substandard and counterfeit medications. Additionally,
digital platforms and mobile applications can empower consumers with tools to verify the
authenticity of medications and report suspected cases of counterfeit drugs (Sunny, et al., 2020;
Liu, et al., 2021).
Furthermore, increasing public awareness and advocacy efforts are essential for sustaining
momentum in medication quality control initiatives. Engaging with communities, healthcare
providers, and civil society organizations can foster a culture of accountability and demand for
quality-assured pharmaceutical products. Empowering consumers with knowledge about
medication safety and regulatory rights can amplify the impact of regulatory interventions and
contribute to improved health outcomes (Erah, 2011; Fokunang, et al., 2011).
RECOMMENDATIONS AND CONCLUSION
The regulatory challenges in medication quality control in Nigeria, including inadequate
regulatory capacity, inconsistent enforcement mechanisms, the proliferation of substandard and
counterfeit medications, limited access to essential medicines, and infrastructural deficiencies,
necessitate comprehensive solutions. Proposed interventions include strengthening regulatory
frameworks, improving regulatory capacity, enhancing enforcement mechanisms, and
promoting public awareness and community engagement.
Enhancing medication quality control is paramount for safeguarding public health and
promoting the growth and sustainability of the pharmaceutical sector in Nigeria. Quality-
assured medications are essential for effective disease management, patient safety, and public
trust in the healthcare system. By ensuring the availability of safe and effective pharmaceutical
products, Nigeria can improve health outcomes, reduce healthcare costs, and stimulate
economic development. Addressing regulatory challenges in medication quality control
requires collective action and collaboration among government agencies, regulatory bodies,
industry stakeholders, healthcare providers, and civil society organizations. Stakeholders must
commit to implementing proposed solutions, allocating resources effectively, and fostering a
culture of compliance with regulatory standards. By working together, Nigeria can overcome
regulatory challenges, enhance medication quality control, and improve public health outcomes
for all its citizens.
In conclusion, prioritizing medication quality control is essential for ensuring access to safe and
effective pharmaceutical products and promoting public health in Nigeria. By addressing
regulatory challenges, implementing comprehensive solutions, and fostering collaboration
among stakeholders, Nigeria can build a robust regulatory framework that safeguards patient
safety, fosters pharmaceutical sector growth, and contributes to the overall well-being of its
population.

Reference
Afolabi, M.O. (2013). A disruptive innovation model for indigenous medicine research: a
Nigerian perspective. African Journal of Science, Technology, Innovation and
Development, 5(6), 445-457.

Eruaga, Itua, & Bature, P.No. 284-294 Page 290

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

Agwu, M.O. (2014). Organizational culture and employees performance in the national agency
for food and drugs administration and control (NAFDAC) Nigeria. Global Journal of
Management and Business Research, 14(2), 1-11.
Akinyandenu, O. (2013). Counterfeit drugs in Nigeria: A threat to public health. African journal
of pharmacy and pharmacology, 7(36), 2571-2576.
Amadi, C., & Tsui, E.K. (2019). How the quality of essential medicines is perceived and
maintained through the pharmaceutical supply chain: A perspective from stakeholders
in Nigeria. Research in Social and Administrative Pharmacy, 15(11), 1344-1357.
Awele, A.C. (2021). A comparative study of Regulatory systems and Quality management
practices in the manufacturing process of different pharmaceutical companies in
Nigeria.
Berendes, S., Adeyemi, O., Oladele, E.A., Oresanya, O.B., Okoh, F., & Valadez, J.J. (2012).
Are patent medicine vendors effective agents in malaria control? Using lot quality
assurance sampling to assess quality of practice in Jigawa, Nigeria.
Buckley, G.J., & Gostin, L.O. eds. (2013). Countering the problem of falsified and substandard
drugs.
Conway, J., Bero, L., Ondari, C., & Wasan, K.M. (2013). Review of the quality of pediatric
medications in developing countries. Journal of Pharmaceutical Sciences, 102(5),
1419-1433.
Cyr, M.E., Etchin, A.G., Guthrie, B.J., & Benneyan, J.C. (2019). Access to specialty healthcare
in urban versus rural US populations: a systematic literature review. BMC HEALTH
SERVICES RESEARCH, 19(1), 1-17.
Diaz, A., Baweja, R., Bonatakis, J.K., & Baweja, R. (2021). Global health disparities in
vulnerable populations of psychiatric patients during the COVID-19 pandemic. World
Journal of Psychiatry, 11(4), 94.
Dixon, J.R. (1999). The international conference on harmonization good clinical practice
guideline. Quality Assurance, 6(2), 65-74.
Douthit, N., Kiv, S., Dwolatzky, T., & Biswas, S. (2015). Exposing some important barriers to
health care access in the rural USA. Public Health, 129(6), 611-620.
Efe, S.I. (2013). Health care problem and management in Nigeria. Journal of Geography and
Regional Planning, 6(6), 244.
Ekeigwe, A.A. (2019). Drug manufacturing and access to medicines: the West African story. A
literature review of challenges and proposed remediation. AAPS Open, 5(1), 3.
Erah, O. (2011). The PharmD program: prospects and challenges in Nigeria. Nigerian Journal
of Pharmaceutical Research, 9(1).
Fokunang, C.N., Ndikum, V., Tabi, O.Y., Jiofack, R.B., Ngameni, B., Guedje, N.M., Tembe-
Fokunang, E.A., Tomkins, , Barkwan, S., Kechia, F., & Asongalem, E., 2011.
Traditional medicine: past, present and future research and development prospects and
integration in the National Health System of Cameroon. African journal of traditional,
complementary and alternative medicines, 8(3).
Galletly, C.L., & Pinkerton, S.D. (2006). Conflicting messages: how criminal HIV disclosure
laws undermine public health efforts to control the spread of HIV. AIDS and
Behavior, 10, 451-461.

Eruaga, Itua, & Bature, P.No. 284-294 Page 291

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

Garuba, H.A., Kohler, J.C., & Huisman, A.M. (2009). Transparency in Nigeria's public
pharmaceutical sector: perceptions from policy makers. Globalization and Health, 5, 1-
13.
Glover, B., Akinbo, O., Savadogo, M., Timpo, S., Lemgo, G., Sinebo, W., Akile, S., Obukosia,
S., Ouedraogo, J., Ndomondo-Sigonda, M., & Koch, M., 2018, July. Strengthening
regulatory capacity for gene drives in Africa: leveraging NEPAD’s experience in
establishing regulatory systems for medicines and GM crops in Africa. In BMC
proceedings (Vol. 12, No. 8, 19-28). BioMed Central.
György, V.R. (2018). Evaluation of the online pharmaceutical market and counterfeit
medicines: Development of a Risk based safety mapping of online pharmaceutical
market.
Haji, S.K. (2023). Poor Accountability and Corruption and its Impact on Quality of Care in the
Public Health Sector within the Kurdistan Region of Iraq (Doctoral dissertation,
University of Portsmouth).
Höllein, L., Kaale, E., Mwalwisi, Y.H., Schulze, M.H., & Holzgrabe, U. (2016). Routine quality
control of medicines in developing countries: analytical challenges, regulatory
infrastructures and the prevalence of counterfeit medicines in Tanzania. TrAC Trends in
Analytical Chemistry, 76, 60-70.
Kohler, J.C., Martinez, M.G., Petkov, M., & Sale, J. (2016). Corruption in the pharmaceutical
sector: diagnosing the challenges.
Lawrence, X.Y., & Woodcock, J. (2015). FDA pharmaceutical quality oversight. International
Journal of Pharmaceutics, 491(1-2), 2-7.
Liang, B.A., & Mackey, T. (2009). Searching for safety: addressing search engine, website, and
provider accountability for illicit online drug sales. American Journal of Law &
Medicine, 35(1), 125-184.
Liu, X., Barenji, A.V., Li, Z., Montreuil, B., & Huang, G.Q. (2021). Blockchain-based smart
tracking and tracing platform for drug supply chain. Computers & Industrial
Engineering, 161, 107669.
Mackey, T.K. (2013). Global health diplomacy and the governance of counterfeit medicines: a
mapping exercise of institutional approaches. Journal of Health Diplomacy, 1(1).
Mukherjee, K. (2019). Quality control and evaluation of herbal drugs: Evaluating natural
products and traditional medicine. Elsevier.
Ncube, B.M., Dube, A., & Ward, K. (2021). Establishment of the African Medicines Agency:
progress, challenges and regulatory readiness. Journal of Pharmaceutical Policy and
Practice, 14, 1-12.
Ndichu, E.T., Ohiri, K., Sekoni, O., Makinde, O., & Schulman, K. (2019). Evaluating the
quality of antihypertensive drugs in Lagos State, Nigeria. PLoS One, 14(2), e0211567.
Ndomondo-Sigonda, M., Miot, J., Naidoo, S., Dodoo, A., & Kaale, E., 2017. Medicines
regulation in Africa: current state and opportunities. Pharmaceutical Medicine, 31, 383-
397.
Nigeria’s, I.W. (2023). Chapter five interaction within Nigeria’s pharmaceutical industry
Adesina Ayobami Oyewale. Domestic Production and Procurement of Medicines in
Nigeria: Capabilities, Challenges and Prospects, 47.

Eruaga, Itua, & Bature, P.No. 284-294 Page 292

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

Nneoma, O., & Obinna, E. (2021). Development of quality indicators for pharmaceutical care
performance assessment in Nigerian community pharmacies: a Delphi panel.
Nsimba, S.E. (2009). Problems associated with substandard and counterfeit drugs in developing
countries: A review article on global implications of counterfeit drugs in the era of anti-
retroviral (ARVS) drugs in a free market economy.
Obuaku, C. (2014). Essential medicines in Nigeria: foregrounding access to affordable essential
medicines. African Sociological Review/Revue Africaine de Sociologie, 18(2), 42-60.
Ogbonna, B.O., Ilika, A.L., & Nwabueze, S.A. (2015). National drug policy in Nigeria, 1985-
2015. World Journal of Pharmacy Research, 4(6), 248-264.
Olowofela, A., Fourrier-Réglat, A., & Isah, A.O. (2016). Pharmacovigilance in Nigeria: an
overview. Pharmaceutical Medicine, 30, 87-94.
Opeyemi, A.A., Obeagu, E.I., & Hassan, A.O. (2024). Enhancing quality healthcare in Nigeria
through medical laboratory services: A review. Medicine, 103(2), e36869.
Pezzola, A., & Sweet, C.M. (2016). Global pharmaceutical regulation: the challenge of
integration for developing states. Globalization and Health, 12, 1-18.
Queen, K., Stanislaus, O., & Mary, D. (2023). Patient Safety in Nigerian Health Care Facilities:
A Review. Asian Journal of Medical Principles and Clinical Practice, 6(2), 224-232.
Raphael, E.C. (2011). Traditional medicine in Nigeria: current status and the future. Research
Journal of Pharmacology, 5(6), 90-94.
Rodrigo, D., Allio, L., & Andres-Amo, (2009). Multi-level regulatory governance: policies,
institutions and tools for regulatory quality and policy coherence.
Roth, L., Bempong, D., Babigumira, J.B., Banoo, S., Cooke, E., Jeffreys, D., Kasonde, L.,
Leufkens, H.G., Lim, J.C., Lumpkin, M., & Mahlangu, G. (2018). Expanding global
access to essential medicines: investment priorities for sustainably strengthening
medical product regulatory systems. Globalization and Health, 14(1), 1-12.
Sunny, J., Undralla, N., & Pillai, V.M. (2020). Supply chain transparency through blockchain-
based traceability: An overview with demonstration. Computers & Industrial
Engineering, 150, 106895.
Taylor, R.B., Shakoor, O., Behrens, R.H., Everard, M., Low, A.S., Wangboonskul, J., Reid,
R.G., & Kolawole, J.A., 2001. Pharmacopoeial quality of drugs supplied by Nigerian
pharmacies. The Lancet, 357(9272), 1933-1936.
Wilson, M.L., Fleming, K.A., Kuti, M.A., Looi, L.M., Lago, N., & Ru, K. (2018). Access to
pathology and laboratory medicine services: a crucial gap. The Lancet, 391(10133),
1927-1938.
World Health Organization, (2000). Guidelines for the regulatory assessment of medicinal
products for use in self-medication (No. WHO/EDM/QSM/00.1). World Health
Organization.
World Health Organization, (2017). WHO Global Surveillance and Monitoring System for
substandard and falsified medical products.
Yakubu, O.P. (2020). An Analysis of Loopholes in the Pharmaceutical Supply Chain, and
Methods for Improving Control of Counterfeit Drugs in Nigeria (Doctoral dissertation,
Griffith College).
Yakubu, R., Isa, A.M., Abubakar, I.J., Oreagba, I., & Awaisu, A. (2020). Drug safety in Nigeria.
In Drug Safety in Developing Countries (pp. 525-556). Academic Press.

Eruaga, Itua, & Bature, P.No. 284-294 Page 293

 International Medical Science Research Journal, Volume 4, Issue 3, March 2024

Zeitz, S., Salami, C.G., Burnham, G., Goings, S.A., Tijani, K., & Morrow, R.H. (1993). Quality
assurance management methods applied to a local‐level primary health care system in
rural Nigeria. The International Journal of Health Planning and Management, 8(3),
235-244.

Eruaga, Itua, & Bature, P.No. 284-294 Page 294